LBA
ETNB

Letko, Brosseau & Associates’s 89bio ETNB Stock Holding History

Letko, Brosseau & Associates’s Portfolio ETNB Stock Details ETNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10,700
Closed -$157K – 102
2025
Q3 		$157K Hold
10,700
– – ﹤0.01% 93
2025
Q2 		$105K Hold
10,700
– – ﹤0.01% 90
2025
Q1 		$77.8K Hold
10,700
– – ﹤0.01% 86
2024
Q4 		$83.7K Hold
10,700
– – ﹤0.01% 98
2024
Q3 		$79.2K Buy
+10,700
New +$90K ﹤0.01% 99

Other funds holding ETNB

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Letko, Brosseau & Associates's ETNB Position: Q4 2025 in Review

Letko, Brosseau & Associates sold out of 89bio (ETNB) in Q4 2025, closing a stake of 10,700 shares — an estimated $157K sold.

Letko, Brosseau & Associates first reported a position in ETNB in Q3 2024 and held it in 5 quarters. The position peaked at $157K in Q3 2025. 2 funds tracked by Wall St. Rank hold ETNB as of Q4 2025.

  • Letko, Brosseau & Associates reported no remaining 89bio position as of Q4 2025 after selling out during the quarter.
  • Letko, Brosseau & Associates sold 10,700 89bio shares in Q4 2025, an estimated $157K.
  • Letko, Brosseau & Associates first reported a position in 89bio in Q3 2024 and held it in 5 quarters.
  • Letko, Brosseau & Associates's 89bio position peaked at $157K in Q3 2025.
  • 2 funds tracked by Wall St. Rank held 89bio as of Q4 2025.

Based on Letko, Brosseau & Associates's 13F filing for Q4 2025, filed 11 Feb 2026.